Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SF2a-TT15
- Development stage
- Phase 2
- Lead developer
- Institut Pasteur
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
SF2a-TT15 is a synthetic carbohydrate-based conjugate vaccine candidate developed to protect against *Shigella flexneri* serotype 2a (SF2a), a major cause of shigellosis and diarrheal disease, particularly in low-income countries. The vaccine consists of a synthetic 15mer oligosaccharide that mimics the O-antigen of *S. flexneri* 2a, covalently linked to tetanus toxoid (TT) as the carrier protein. This design aims to induce robust immune responses by presenting both B-cell and T-cell epitopes. Clinical studies have shown that SF2a-TT15 is safe, well tolerated, and highly immunogenic in healthy adults, inducing strong IgG and IgA antibody responses as well as long-lived memory B cells specific for SF2a LPS. The immune response has been observed to persist for at least three years post-vaccination. The vaccine is being developed by Institut Pasteur.
- Other names
- SF2a-TT15 vaccineSF-2a-TT15 vaccineSF 2a-TT15 vaccine
Beyond the preview
Go deeper on SF2a-TT15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SF2a-TT15.